Cogent Biosciences, Inc. (COGT) News
Filter COGT News Items
COGT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest COGT News From Around the Web
Below are the latest news stories about Cogent Biosciences Inc that investors may wish to consider to help them evaluate COGT as an investment opportunity.
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Analysts’ Top Healthcare Picks: Albireo Pharma (ALBO), Cogent Biosciences (COGT)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma (ALBO – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Albireo Pharma (ALBO) Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma today and set a price target of $84.00. The company's shares closed last Wednesday at $24.31. According to TipRanks. |
Cogent Biosciences Provides 2022 Corporate GuidanceCogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided 2021 year-end updates and corporate guidance for 2022. |
Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare ConferenceCogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President will participate in a fireside chat and one-on-one investor meetings during the Piper Sandler 33rd Annual Healthcare Conference, taking place virtually November 29 – December 2, 2021. |
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial ResultsCogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the third quarter ended September 30, 2021 and provided corporate updates. |
Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. |
Hedge Funds Are Dumping Cogent Biosciences, Inc. (COGT)Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […] |
2 “Strong Buy” Stocks Under $10 With Over 100% Upside PotentialFor investors seeking the best returns, the decision of where to put the initial investment typically comes down to two choices. Put all the eggs in one big basket, and buy into the market’s giant corporations, the trillion-dollar companies with famously high share prices and a track record of steady growth – or to buy low, find a group of low-cost stocks in companies with sound business footings and high potential upside. It all comes down to just how much of a return do you want. The market's three biggest companies, Apple, Microsoft, and Google, have upsides running between 10% and 20% for the year ahead. |
Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain PenetrationCogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data providing further evidence of bezuclastinib as a differentiated, potent, and selective KIT inhibitor. The data were presented in a virtual poster at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. |
Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC ConferenceCogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the Company will present preclinical data on bezuclastinib at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics held October 7-10, 2021. |